Evidence check: Menopause Check in the context of Fruchtbarkeit

The question of a 'Menopause Check' in the context of fertility requires a nuanced, evidence-based assessment. Typical biomarkers such as anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B are used to estimate ovarian reserve – the remaining egg count. Evidence for the link between AMH and the timing of menopause is human-strong: studies show low AMH is associated with earlier menopause. However, the predictive power for individual fertility (e.g., chance of natural conception) is much weaker. AMH does not directly predict egg quality or pregnancy probability; it rather indicates the remaining reproductive window. Reference ranges vary by age, lab, and assay. Therefore, a menopause check can serve as a rough guide but should not be the sole basis for family planning or fertility treatment decisions. The evidence level is human-moderate: clinical use is established, but interpretation for individual fertility has limitations. Caveat: consumer DNA tests often provide only partial information and lack clinical diagnostic depth. Gynecological consultation is essential.